We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-13.93%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$145M
AUM Growth
-$28.6M
Cap. Flow
-$1.67M
Cap. Flow %
-1.15%
Top 10 Hldgs %
75.3%
Holding
32
New
2
Increased
12
Reduced
8
Closed
7

Top Buys

1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.7M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$2.53M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$2.06M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$1.54M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.3M

Top Sells

1
EBS icon
Emergent Biosolutions
EBS
+$2.36M
2
CPIX icon
Cumberland Pharmaceuticals
CPIX
+$2M
3
CHMA
Chiasma, Inc. Common Stock
CHMA
+$1.56M
4
VSTM icon
Verastem
VSTM
+$1.48M
5
MTNB icon
Matinas BioPharma
MTNB
+$1.29M

Sector Composition

1 Healthcare 93.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
26
Collegium Pharmaceutical
COLL
$1.17B
– –
-60,045
Closed -$909K
DMAC icon
27
DiaMedica Therapeutics
DMAC
$393M
– –
-250,000
Closed -$1.14M
EBS icon
28
Emergent Biosolutions
EBS
$394M
– –
-46,800
Closed -$2.36M
VSTM icon
29
Verastem
VSTM
$530M
– –
-41,667
Closed -$1.48M
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.6B
– –
-98,860
Closed -$1M
CHMA
31
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-300,000
Closed -$1.56M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Stonepine Capital Management held 32 positions worth $145M, down 16% from $174M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Stonepine Capital Management's Q2 2019 filing shows 2 new, 12 increased, 8 reduced and 7 closed positions. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K. The largest sale was Emergent Biosolutions, an estimated $2.36M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2019 buy was Novelion Therapeutics Inc. Common Shares: 491,096 shares worth $383K.
  • Stonepine Capital Management added most to BioDelivery Sciences International, Inc. in Q2 2019, an estimated $5.7M increase.
  • Stonepine Capital Management's biggest Q2 2019 reduction was Cumberland Pharmaceuticals, cutting an estimated $2M.
  • Stonepine Capital Management fully exited Emergent Biosolutions in Q2 2019, selling an estimated $2.36M.
  • Stonepine Capital Management's ten largest holdings make up 75% of its $145M portfolio in Q2 2019.
  • Stonepine Capital Management opened 2 new positions and closed 7 in Q2 2019.
  • Stonepine Capital Management's portfolio value fell 16% quarter-over-quarter to $145M.

Based on Stonepine Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.